Pharmaceutical Compositions for the Treatment of Cellulite
MXPA05011430A
Nk-2 antagonist basic linear compounds and formulations containing them.
WO2004052923A2
Process for the preparation of bicyclic hexa-peptide nepadutant
EG26672A
Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
TWI304406B
Process for the preparation of (e)-5-(2-bromovinyl)-2'-deoxyuridine
DE10162593A1
Stabilized topical brivudine formulations
YU37303A
Process for the synthesis of optically active anthracyclines
EP1297826A1
Nasal pharmaceutical compositions containing a NK-2 antagonist
AU1049502A
Basic compounds containing tertiary amides with activity on tachykinin receptors, and pharmaceutical compositions containing them
DE10130128A1
Treatment of herpes zoster infections or post-herpetic neuralgia by once-daily oral administration of brivudine, giving superior results to higher dose and more frequent administration of acyclovir
DE10109657A1
Process for the preparation of (E) -5- (2-bromovinyl) -2`-deoxyuridine
EP1224210A2
Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them
HU0200208A2
L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them and their use
CN1324406A
DNA molecules encoding MUC-1 and use thereof in tumor vaccination
AU5745799A
Basic products having antagonistic activity on the nk-1 receptor and their use in pharmaceutical compositions
WO0008049A1
Cyclic peptides with antagonistic activity specific for bradykinin b2 receptor and formulations containing them
TW491857B
Monocyclic compounds having NK-2 antagonist action and compositions containing them
AU1026399A
Pharmaceutical compositions containing ricinoleic acid and their use in anti-inflammatory and analgesic therapy
